FIELD: chemistry.
SUBSTANCE: invention relates to novel estratrien-triazoles of general formula (I), which are useful in therapy, especially in treating and/or preventing steroid hormone dependent disorders, preferably steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.
EFFECT: improved method.
21 cl
Title | Year | Author | Number |
---|---|---|---|
17β-HSD1 AND STS INHIBITORS | 2006 |
|
RU2412196C2 |
NEW INHIBITORS OF 17 β-HYDROXYSTEROID-DEHYDROGENASE TYPE I | 2004 |
|
RU2369614C2 |
COMPOUNDS, SET, ANDROGENIC COMPOSITION | 2000 |
|
RU2242479C2 |
NOVEL COMPOUNDS AND USE THEREOF IN THERAPY | 2004 |
|
RU2412190C2 |
METHOD OF RESIDUAL LIPOPROTEINS PRODUCING INHIBITION | 2004 |
|
RU2330682C2 |
INSECTICIDE ANTHRANYLAMIDES | 2001 |
|
RU2278852C2 |
BICYCLIC DERIVATIVES AS CEPT INHIBITORS | 2007 |
|
RU2430917C2 |
AZOLE COMPOUNDS WITH NEUTROTHERAPEUTIC ACTIVITY | 2006 |
|
RU2418792C2 |
17 β -OXYESTRATRIENES | 2002 |
|
RU2339643C2 |
PROTEIN KINASE INHIBITOR (VERSIONS), USE THEREOF FOR TREATING ONCOLOGICAL DISEASES AND BASED PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2477723C2 |
Authors
Dates
2012-12-10—Published
2007-09-17—Filed